Sorry, this activity has expired and is no longer available for CME credit. You may still enjoy the program.
CME Information
Sponsorship Statement: This continuing education activity is sponsored by 
.
Support Statement: This activity is supported, in part, by educational grants from
.
Target Audience: The intended audience for this activity is retina specialists and other healthcare professionals involved in the treatment of patients with retina disorders.
Learning Objectives: At the conclusion of this activity participants should be able to:
- Incorporate new clinical evidence into practice on the use of intravitreal steroid implants in the treatment of retinal disorders to ensure provision of effective therapy to patients with this disease.
- Evaluate the published studies of ranibizumab in the treatment of retinal disease to facilitate the design of optimal therapeutic regimens.
- Review current literature describing the safety of intravitreal bevacizumab and compare its effectiveness with that of other anti-VEGF agents.
- Assess current evidence-based data on the mechanism of action, pharmacokinetics, safety and efficacy of aflibercept in the treatment of retinal disease.
Contributing Faculty:
Michael W. Stewart, MD
Associate Professor and Chairman
Department of Ophthalmology
Mayo Clinic Florida
Reviewer:
Ronald A. Codario, MD, FACP, CCMEP
Accreditation:
Vindico Medical Education is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
Credit Designation:
Vindico Medical Education designates this enduring material for a maximum of 0.50 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
This enduring material is approved for 1 year from the date of original release, May 16, 2013 to May 15, 2014.
How To Participate in this Activity and Obtain CME Credit:
To participate in this CME activity, you must read the objective, watch the presentation, complete the CME posttest, and fill in the evaluation. Provide only one (1) correct answer for each question. A satisfactory score is defined as answering the posttest question correctly. Upon receipt of the completed materials, if a satisfactory score on the posttest is achieved, Vindico Medical Education will issue an AMA PRA Category 1 Credit(s)™ Certificate.
Disclosures:
In accordance with the Accreditation Council for Continuing Medical Education’s Standards for Commercial Support, all CME providers are required to disclose to the activity audience the relevant financial relationships of the planners, teachers, and authors involved in the development of CME content. An individual has a relevant financial relationship if he or she has a financial relationship in any amount occurring in the last 12 months with a commercial interest whose products or services are discussed in the CME activity content over which the individual has control.
The authors disclose that they do have significant financial interests in any products or class of products discussed directly or indirectly in this activity, including research support.
Planning Committee and Faculty members report the following relationship(s):
Michael W. Stewart, MD
Consulting Fees: Allergan, Boehringer Ingelhein, Regeneron
Contracted Research: Regeneron
Discussion of off-label use: Bevacizumab (Genentech)
Carmen A. Puliafito, MD (Planning Committee)
Grants/Research Support: Carl Zeiss Meditec
Reviewer reports the following relationship(s):
Ronald A. Codario, MD, FACP, CCMEP
No relevant financial relationships to disclose.
Vindico Medical Education staff report the following relationship(s):
No relevant financial relationships to disclose.
Signed disclosures are on file at Vindico Medical Education, Office of Medical Affairs and Compliance.
Unlabeled and Investigational Usage:
The audience is advised that this continuing medical education activity may contain references to unlabeled uses of FDA-approved products or to products not approved by the FDA for use in the United States. The faculty members have been made aware of their obligation to disclose such usage. All activity participants will be informed if any speakers/authors intend to discuss either non-FDA approved or investigational use of products/devices.
Copyright Statement:
Created and published by Vindico Medical Education, 6900 Grove Road, Building 100, Thorofare, NJ 08086-9447. Telephone: 856-994-9400; Fax: 856-384-6680. Printed in the USA. Copyright © 2013 Vindico Medical Education. All rights reserved. No part of this publication may be reproduced without written permission from the publisher. The material presented at or in any of Vindico Medical Education continuing medical education activities does not necessarily reflect the views and opinions of Vindico Medical Education. Neither Vindico Medical Education nor the faculty endorse or recommend any techniques, commercial products, or manufacturers. The faculty/authors may discuss the use of materials and/or products that have not yet been approved by the US Food and Drug Administration. All readers and continuing education participants should verify all information before treating patients or utilizing any product.